Search Results

You are looking at 291 - 300 of 2,716 items for :

  • Refine by Access: All x
Clear All
Full access

Role of Molecular Profiling in Soft Tissue Sarcoma

Timothy Lindsay and Sujana Movva

this current review. In routine practice, fluorescence in situ hybridization (FISH) and reverse transcription-polymerase chain reaction (RT-PCR) are used to detect tumor-specific alterations, such as translocations, gene fusions, and amplifications

Full access

CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers

Linda M. Sutton, Joseph Geradts, Erika P. Hamilton, Kathleen A. Havlin, Gretchen G. Kimmick, P. Kelly Marcom, Neil L. Spector, Melanie Watson, Daniel U. Rabin, Theodore O. Bruno, Amanda Noe, Stacy Miller, Chitra Subramaniam, Sherry Layton, and Katherine Grichnik

' coping with cancer, comparing information from chart reviews before and after the PI-CME activity. Table 1 CHAMBER Clinical Gaps, Corresponding Learning Objectives, Performance Metrics, and Comparators Methods Target Audience

Full access

Hypofractionated Whole Breast Radiation and Partial Breast Radiation for Early-Stage Breast Cancers: An Update on Progress

Beryl McCormick

completed accrual. Therefore, some data are beginning to appear in peer-reviewed journals, although not with the clarity of results anticipated. In response to the growing use of PBI off-trial, the American Society for Radiation Oncology (ASTRO) convened a

Full access

Optimal Surveillance Strategies After Surgery for Renal Cell Carcinoma

Mark D. Tyson and Sam S. Chang

RG . Excise, ablate or observe: the small renal mass dilemma—a meta-analysis and review . J Urol 2008 ; 179 : 1227 – 1233 ; discussion 1233–1234 . 36. Klatte T Grubmüller B Waldert M . Laparoscopic cryoablation versus partial

Full access

Use of Endobronchial Ultrasound and Endoscopic Ultrasound to Stage the Mediastinum in Early-Stage Lung Cancer

Christopher Gilbert, Lonny Yarmus, and David Feller-Kopman

participation. To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the post-test with a 70% minimum passing score and complete the evaluation at http

Full access

Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer

Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching

-level analysis conducted by Cortazar et al. 13 No TNBC-specific outcomes were reported in any of those trial publications. Data from those RCTs were therefore not identified by our literature review or included in the primary analysis. The ORs of pCR and the HRs

Full access

NCCN Task Force Report: Management of Neuropathy in Cancer

Michael D. Stubblefield, Harold J. Burstein, Allen W. Burton, Christian M. Custodio, Gary E. Deng, Maria Ho, Larry Junck, G. Stephen Morris, Judith A. Paice, Sudhakar Tummala, and Jamie H. Von Roenn

1996 ; 46 : 108 – 111 . 39 Badros A Goloubeva O Dalal JS . Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature . Cancer 2007 ; 110 : 1042 – 1049 . 40 Jagannath S

Full access

Interpretation of Genetic Testing for Lynch Syndrome in Patients With Putative Familial Colorectal Cancer

Christina Rybak and Michael J. Hall

-fixed, paraffin-embedded tissue. An advantage of immunohistochemical testing is that it can be performed in the pathology department of most hospitals, whereas MSI testing requires molecular facilities. Based on a recent extensive evidence review by the EGAPP, the

Full access

NCCN Guidelines as a Model of Extended Criteria for Lung Cancer Screening

Brady J. McKee, Shawn Regis, Andrea K. Borondy-Kitts, Jeffrey A. Hashim, Robert J. French Jr, Christoph Wald, and Andrea B. McKee

, between our group 1 and 2 populations. Methods This retrospective single-center study was approved by the Lahey Hospital & Medical Center (LHMC) Institutional Review Board. We report results of consecutive individuals from LHMC who underwent

Full access

Updates to the Management of Chronic Lymphocytic Leukemia

William G. Wierda

patients with relapsed CLL, even in those with high-risk features. “Outcomes were similar regardless of IGHV mutation status or whether or not a patient had del(17p),” he added. Finally, Dr. Wierda briefly reviewed results with the BCL-2 inhibitor